EUVIMEDEUVIMED entdecken
Crossref

Light-emitting anticancer Pt-cyclometalated phenanthroimidazole complexes

Somayee Heydari, Hashem Shahroosvand, Abbas Bahari, Sebastiano Bellani

Journal of Inorganic Biochemistry · 2026

DOI: 10.1016/j.jinorgbio.2025.113121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Inorganic Biochemistry, 2026. Verfasst von Somayee Heydari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Group for Molecular Engineering of Advanced Functional Materials (GMA), Chemistry Department, University of Zanjan, Zanjan, Iran. Hauptthemen laut MEDLINE: Antineoplastic Agents, Imidazoles, Coordination Complexes, Platinum. Die Arbeit nennt 102 Literaturangaben. Gefördert von: University of Zanjan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Designing drugs that selectively target cancer cells while sparing healthy ones remains a major challenge in cancer chemotherapy. In this study, four new Pt-cyclometalated complexes containing a pipyridine core and varied phenanthroimidazole-based ligands were synthesized and comprehensively characterized to evaluate their potential as selective anticancer agents with reduced toxicity toward peripheral blood mononuclear cells. Through molecular engineering via substitution on the imidazole moieties, these complexes exhibit tunable emission properties, with colors ranging from blue (475 nm) to green (610 nm) and high photoluminescence quantum yields exceeding 60 %, underscoring their promise as luminescent anticancer systems. Biological evaluations, including flow cytometry, cell cycle analysis, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assays, revealed that complexes with simpler, unsubstituted imidazole frameworks displayed the strongest anticancer activity, correlating with their higher quantum yields and stronger binding affinities toward both double-stranded DNA (dsDNA) and G-quadruplex DNA (G4DNA). Overall, these findings demonstrate that phenanthroimidazole-containing Pt-cyclometalated complexes represent a promising class of light-emitting anticancer agents with potential for selective and efficient cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsImidazolesCoordination ComplexesPlatinumHumansPhenanthrolinesG-QuadruplexesLightCell Line, Tumor

Stichwörter der Autor:innen

AnticancerG-quadruplex recognitionLuminescenceMetal complexesPhenanthroimidazole ligandsPt-cyclometalated complexes

Substanzen

Antineoplastic AgentsImidazolesCoordination ComplexesPhenanthrolinesPlatinum

Autor:innen und Institutionen

  • Group for Molecular Engineering of Advanced Functional Materials (GMA), Chemistry Department, University of Zanjan, Zanjan, Iran.
  • Group for Molecular Engineering of Advanced Functional Materials (GMA), Chemistry Department, University of Zanjan, Zanjan, Iran. Electronic address: shahroos@znu.ac.ir.
  • Research institute of modern biological techniques, University of Zanjan, Zanjan, Iran. Electronic address: bahari@znu.ac.ir.
  • Antares Electrolysis S.r.l., Piazza della Vittoria 14/19, 16121 Genova, Italy. Electronic address: sebastiano.bellani@antares-electrolysis.com.

Förderung

  • University of Zanjan

Zitieren

APA

Heydari, S., Shahroosvand, H., Bahari, A., & Bellani, S. (2026). Light-emitting anticancer Pt-cyclometalated phenanthroimidazole complexes. Journal of Inorganic Biochemistry. https://doi.org/10.1016/j.jinorgbio.2025.113121

Vancouver

Heydari S, Shahroosvand H, Bahari A, Bellani S. Light-emitting anticancer Pt-cyclometalated phenanthroimidazole complexes. Journal of Inorganic Biochemistry. 2026. doi:10.1016/j.jinorgbio.2025.113121

BibTeX
@article{Heydari2026,
  author = {Heydari, Somayee and Shahroosvand, Hashem and Bahari, Abbas and Bellani, Sebastiano},
  title = {Light-emitting anticancer Pt-cyclometalated phenanthroimidazole complexes},
  journal = {Journal of Inorganic Biochemistry},
  year = {2026},
  doi = {10.1016/j.jinorgbio.2025.113121}
}
Kostenlos starten →